Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier:
NCT00949039
First received: July 7, 2009
Last updated: March 11, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)